- Home
- S vs PTGX Comparison
S vs PTGX Comparison
Compare S & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.3B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | S | PTGX |
|---|---|---|
| Price | $22.99 | $142.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 13 |
| Target Price | $19.28 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 8.1M | 543.5K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $1,001,278,000.00 | N/A |
| Revenue This Year | $22.84 | $874.25 |
| Revenue Next Year | $17.32 | N/A |
| P/E Ratio | ★ N/A | $60.58 |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $62.24 |
| 52 Week High | $24.40 | $160.81 |
Technical Indicators
Market Signals| Indicator | S | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 47.70 |
| Support Level | $12.57 | $141.95 |
| Resistance Level | N/A | $151.24 |
| Average True Range (ATR) | 1.16 | 5.01 |
| MACD | 0.09 | -0.65 |
| Stochastic Oscillator | 72.64 | 51.40 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.